Claims for Patent: 5,948,758

Summary for Patent: 5,948,758

Title:	Methods for treating various disease states by reducing adhesion of leukocytes of target cells
Abstract:	The invention relates to therapeutic methods of using a substantially pure protein comprising the .beta.-subunit of a human glycoprotein involved in cellular adhesion, or a biologically active fragment thereof, or analog thereof. These therapeutic methods are useful for treating auto immune diseases and allograft rejection.
Inventor(s):	Springer; Timothy (Chestnut Hill, MA), Kishimoto; Takashi K. (Cambridge, MA), Roberts; Thomas M. (Cambridge, MA)
Assignee:	Dana Faber Cancer Institute Inc. (Boston, MA)
Application Number:	08/811,027
Patent Claims:	1. A method for inhibiting a LFA-1, MacI, or p150,90 mediated leukocyte immune response in an animal comprising administering to said animal a pharmaceutical composition comprising a fragment of the extracellular domain of the .beta. subunit of LFA-1 in admixture with a pharmaceutically acceptable carrier, wherein said fragment inhibits said leukocyte immune response and said pharmaceutical composition comprises an amount of said fragment effective for inhibiting said leukocyte immune response. 2. The method of claim 1, wherein said animal is suffering from a disease selected from the group consisting of an autoimmune disease, allograft rejection, and graft-versus-host disease. 3. The method of claim 2, wherein said disease is selected from the group consisting of: systemic lupus erythematosis, juvenile onset diabetes, multiple sclerosis, allergic conditions, eczema, ulcerated colitis, inflammatory bowel disease, and Crohn's disease. 4. The method of claim 2, wherein said disease is rheumatoid arthritis. 5. A method for inhibiting a LFA-1, Mac1, or p150,90 mediated leukocyte immune response in an animal comprising administering to said animal a pharmaceutical composition comprising the extracellular domain of the .beta. subunit of LFA-1 in admixture with a pharmaceutically acceptable carrier, wherein said pharmaceutical composition comprises an amount of said extracellular domain effective for inhibiting said leukocyte immune response. 6. The method of claimed in claim 5, wherein said extracellular domain comprises amino acids 23-700 of FIG. 1. 7. The method of claim 5, wherein said animal is suffering from a disease selected from the group consisting of an autoimmune disease, allograft rejection, and graft-versus-host disease. 8. The method of claim 7, wherein said disease is selected from the group consisting of: systemic lupus erythematosis, juvenile onset diabetes, multiple sclerosis, allergic conditions, eczema, ulcerated colitis, inflammatory bowel disease, and Crohn's disease. 9. The method of claim 7, wherein said disease in rheumatoid arthritis.

Details for Patent 5,948,758

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Vericel Corporation	MACI	autologous cultured chondrocytes on porcine collagen membrane	Cell Sheets	125603	12/13/2016		2007-02-26